Review
Copyright ©The Author(s) 2021.
World J Meta-Anal. Jun 28, 2021; 9(3): 220-233
Published online Jun 28, 2021. doi: 10.13105/wjma.v9.i3.220
Table 1 Studies showing liver function abnormalities in coronavirus disease 2019 patients
No.StudyFindingRef.
1Large scale study: n = 1099AST/ALT were elevated in 18.2%/19.8% of mild COVID-19 patientsand 39.4%/28.1% in severe COVID-19 patientsGuan et al[7]
2Small scale study: n = 41AST was elevated in 62% of patients in the ICU compared with 25% in those who did not require care in the ICUHuang et al[8]
3n = 99AST (U/L): All patients: 34 (26-48); ALT (U/L): All patients: 39 (21-55)Chen et al[17]
4n = 113AST (U/L): All patients: 16 (22-46); ALT (U/L): All patients: 22%; Deaths: 27%Chen et al[25]
5n = 115AST (U/L): All patients: 28.3 ± 15.6; ULN ≤ 50 U/L: 85%; 50-150 U/L: 15%; > 150: None; ALT (U/L): All patients: 34 (18-67); Moderate: 28 (21-43.5); Severe: 36.5 (17.5-71.5)Zhang et al[30]
6French Cohort Study, n = 281 patients102 (36.3%) patients had liver dysfunctions. High level of GGT was the most common perturbation (25.3%). Elevated levels of AST (24.3%) and ALT (12.8%)Chaibi et al[81]
7Large scale study: China, n = 350ALT (U/L) and AST (U/L) were profoundly elevated in critically ill patients (33; 49) in comparison to severe patients (23; 29) and mild patients (22; 26)Fu et al[82]
8n = 79AST (U/L): All patients: 30 (20-50); Moderate: 28 (22-48); Severe: 35 (22-55). ALT (U/L): All patients: 34 (18-67); Moderate: 28 (21-43.5); Severe: 36.5 (17.5-71.5)Xie et al[83]
9n = 104ALT (U/L) and AST (U/L) were profoundly elevated in patients (36.5; 33)Li et al[84]
10Large scale study: China, n = 657ALT (U/L) was highly elevated in critically ill patients (41) in comparison to moderate patients (25)Wang et al[85]
11Large scale study: China, n = 1827AST (U/L): Abnormal in pre-hospitalization patients (20.3%); Admission (66.9%) and peak hospitalization (83.4%) patients with COVID-19; ALT (U/L): Abnormal in pre-hospitalization patients (19.1%); Admission (41.6%) and peak hospitalization (61.6%) patients with COVID-19 infectionHundt et al[86]
12Large scale study: New York, n = 570058.4% developed AST values > 40U/L and 39% ALT > 60U/L. 56 patients (2.1%) developed acute hepatic injury defined as an elevation in AST or ALT of >15 times the upper limit of normalRichardson et al[87]